Emerging oligonucleotide therapeutics for rare neuromuscular diseases
Research and drug development concerning rare diseases are at the cutting edge of scientific technology. To date, over 7,000 rare diseases have been identified. Despite their individual rarity, 1 in 10 individuals worldwide is affected by a rare condition. For the majority of these diseases, there i...
Autors principals: | Aoki, Y, Wood, MJA |
---|---|
Format: | Journal article |
Idioma: | English |
Publicat: |
IOS Press
2021
|
Ítems similars
-
Oligonucleotide-based therapies for neuromuscular disease
per: Douglas, A, et al.
Publicat: (2015) -
Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases
per: Tsoumpra, MK, et al.
Publicat: (2019) -
Advances in oligonucleotide drug delivery
per: Roberts, TC, et al.
Publicat: (2020) -
Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseases
per: Ashok Verma
Publicat: (2018-01-01) -
Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment
per: Gait, M, et al.
Publicat: (2018)